Branded Oncology Products

Product Details:

• Fulvenat an anti-estrogen drug, is prescribed for the treatment of estrogen-related breast cancers. The drug inhibits the action of estrogen and prevents the growth of estrogen-dependent cancer cells. Fulvestrant is also prescribed in postmenopausal women with drug-resistant breast cancer.

• not previously treated with endocrine therapy, or- with disease relapse on or after adjuvant antioestrogen therapy, or disease progression on antioestrogen therapy.
• In combination with palbociclib for the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer in women who have received prior endocrine therapy.
• In pre- or perimenopausal women, the combination treatment with palbociclib should be combined with a luteinising hormone releasing hormone (LHRH) agonist.

Product Details:

• In the treatment of metastatic prostate cancer where Zoladex has demonstrated comparable survival benefits to surgical castrations
• In the treatment of locally advanced prostate cancer, as an alternative to surgical castration where Zoladex has demonstrated comparable survival benefits to an anti-androgen
• As adjuvant treatment to radiotherapy in patients with high-risk localised or locally advanced prostate cancer where Zoladex has demonstrated improved disease-free survival and overall survival
• As neo-adjuvant treatment prior to radiotherapy in patients with high-risk localised or locally advanced prostate cancer where Zoladex has demonstrated improved disease-free survival
• As adjuvant treatment to radical prostatectomy in patients with locally advanced prostate cancer at high risk of disease progression where Zoladex has demonstrated improved disease-free survival
• Advanced breast cancer in pre and perimenopausal women suitable for hormonal manipulation.
• Zoladex 3.6 mg is indicated as an alternative to chemotherapy in the standard of care for pre/perimenopausal women with oestrogen receptor (ER) positive early breast cancer.
• Endometriosis: In the management of endometriosis, Zoladex alleviates symptoms, including pain, and reduces the size and number of endometrial lesions.
• Endometrial thinning: Zoladex is indicated for the prethinning of the uterine endometrium prior to endometrial ablation or resection.
• Uterine fibroids: In conjunction with iron therapy in the haematological improvement of anaemic patients with fibroids prior to surgery.
• Assisted reproduction: Pituitary downregulation in preparation for superovulation.

Product Details:

• With or without total body irradiation (TBI), as conditioning treatment prior to allogeneic or autologous haematopoietic progenitor cell transplantation (HPCT) in haematological diseases in adult and paediatric patients;
• When high dose chemotherapy with HPCT support is appropriate for the treatment of solid tumours in adult and paediatric patients.

Product Details:

• Paclitax NAB monotherapy is indicated for the treatment of metastatic breast cancer in adult patients who have failed first-line treatment for metastatic disease and for whom standard, anthracycline containing therapy is not indicated.
• Paclitax NAB in combination with gemcitabine is indicated for the first-line treatment of adult patients with metastatic adenocarcinoma of the pancreas.
• Paclitax NAB in combination with carboplatin is indicated for the first-line treatment of non-small cell lung cancer in adult patients who are not candidates for potentially curative surgery and/or radiation therapy.

Product Details:

• Temsirolimus is indicated for the first-line treatment of adult patients with advanced renal cell carcinoma (RCC) who have at least three of six prognostic risk factors.

• Temsirolimus is indicated for the treatment of adult patients with relapsed and/or refractory mantle cell lymphoma (MCL).

Product Details:

• As monotherapy for the treatment of those patients who have received at least two chemotherapy regimens for their metastatic disease. Prior chemotherapy must have included at least an anthracycline and a taxane unless patients are unsuitable for these treatments. Hormone receptor positive patients must also have failed hormonal therapy, unless patients are unsuitable for these treatments.
• In combination with paclitaxel for the treatment of those patients who have not received chemotherapy for their metastatic disease and for whom an anthracycline is not suitable.
• In combination with docetaxel for the treatment of those patients who have not received chemotherapy for their metastatic disease.
• In combination with an aromatase inhibitor for the treatment of postmenopausal patients with hormone-receptor positive MBC, not previously treated with trastuzumab.

• Hertraz is indicated for the treatment of adult patients with HER2 positive early breast cancer. (EBC).
• Following surgery, chemotherapy (neoadjuvant or adjuvant) and radiotherapy (if applicable).
• Following adjuvant chemotherapy with doxorubicin and cyclophosphamide, in combination with paclitaxel or docetaxel.
• In combination with adjuvant chemotherapy consisting of docetaxel and carboplatin.
• In combination with neoadjuvant chemotherapy followed by adjuvant Hertraz therapy, for locally advanced (including inflammatory) disease or tumours > 2 cm in diameter.
• Hertraz should only be used in patients with metastatic or early breast cancer whose tumours have either HER2 overexpression or HER2 gene amplification as determined by an accurate and validated assay.

• Hertraz in combination with capecitabine or 5-fluorouracil and cisplatin is indicated for the treatment of adult patients with HER2 positive metastatic adenocarcinoma of the stomach or gastro-esophageal junction who have not received prior anti-cancer treatment for their metastatic disease.
• Hertraz should only be used in patients with metastatic gastric cancer (MGC) whose tumours have HER2 overexpression as defined by IHC2+ and a confirmatory SISH or FISH result, or by an IHC 3+ result.

Product Details:

• Intermediate-2 and high-risk myelodysplastic syndromes (MDS) according to the International Prognostic Scoring System (IPSS),
• Chronic myelomonocytic leukaemia (CMML) with 10-29 % marrow blasts without myeloproliferative disorder,
• Acute myeloid leukaemia (AML) with 20-30 % blasts and multi-lineage dysplasia, according to World Health Organisation (WHO) classification,
• AML with >30% marrow blasts according to the WHO classification.

Product Details:

• Nimotuzumab is a monoclonal antibody and an endothelial growth factor receptor (EGRF) antagonist.
• It also stimulates the immune system against the cancer cells.
• It is a targeted therapy used for the treatment of glioma (cancer in the brain and spinal cord), cancer of the head and neck, and nasopharyngeal cancer.
• It prevents the growth and spread of the cancer.

Product Details:

Product Details:

FLOTAXL USE TO TREAT Breast Cancer (BC):

                        Non-Small Cell Lung Cancer (NSCLC)

                        Hormone Refractory Prostate Cancer (HRPC)

                        Gastric Adenocarcinoma (GC)

                        Squamous Cell Carcinoma of the Head and Neck Cancer (SCCHN)

 It binds to B-subunit of tubulin & interfere the microtubules segregation to daughter cells  by causing hyper-polyerization of microtubule in G2/M-phase of cell division

Product Details:

• The treatment of newly diagnosed high risk metastatic hormone sensitive prostate cancer (mHSPC) in adult men in combination with androgen deprivation therapy (ADT)
• The treatment of metastatic castration resistant prostate cancer (mCRPC) in adult men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated
• The treatment of mCRPC in adult men whose disease has progressed on or after a docetaxel-based chemotherapy regimen.

Product Details:

• Carcinoma of the prostate, especially in cases unresponsive to, or relapsing after, treatment by conventional oestrogens (stilboestrol, polyoestradiol phosphate etc.) or by orchidectomy.

Product Details:

• The treatment of newly diagnosed high risk metastatic hormone sensitive prostate cancer (mHSPC) in adult men in combination with androgen deprivation therapy (ADT)
• The treatment of metastatic castration resistant prostate cancer (mCRPC) in adult men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated
• The treatment of mCRPC in adult men whose disease has progressed on or after a docetaxel-based chemotherapy regimen.

Product Details:

• Sorafenib is used to treat kidney, liver, and thyroid cancer. It is a chemotherapy drug that works by slowing or stopping the growth of cancer cells.

• Nexavar is indicated for the treatment of hepatocellular carcinoma.

• Nexavar is indicated for the treatment of patients with advanced renal cell carcinoma who have failed prior interferon-alpha or interleukin-2 based therapy or are considered unsuitable for such therapy.

• Nexavar is indicated for the treatment of patients with progressive, locally advanced or metastatic, differentiated (papillary/follicular/Hürthle cell) thyroid carcinoma, refractory to radioactive iodine.

Product Details:

• Sorafenib is used to treat kidney, liver, and thyroid cancer. It is a chemotherapy drug that works by slowing or stopping the growth of cancer cells.

• Sorafenib is indicated for the treatment of hepatocellular carcinoma.

• Sorafenib is indicated for the treatment of patients with advanced renal cell carcinoma who have failed prior interferon-alpha or interleukin-2 based therapy or are considered unsuitable for such therapy.

• Sorafenib is indicated for the treatment of patients with progressive, locally advanced or metastatic, differentiated (papillary/follicular/Hürthle cell) thyroid carcinoma, refractory to radioactive iodine.

Product Details:

Product Details:

• Erlotinib is Non-Small-Cell Lung Cancer (NSCLC). Erlotinib is indicated as monotherapy for the treatment of patients with locally advanced or metastatic NSCLC after failure of at least one prior chemotherapy regimen.

Product Details:

• Pemetrexed in combination with Cisplatin is indicated for the treatment of chemotherapy-naive patients with unresectable malignant pleural mesothelioma. Pemetrexed in combination with Cisplatin is indicated as a first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology. Pemetrexed is indicated as a monotherapy for the maintenance treatment of locally advanced or metastatic Non Small Cell Lung Cancer (NSCLC) other than predominantly squamous cell histology in patients whose disease has not progressed immediately following platinum-based therapy.

Product Details:

• Melphalan Tablets are indicated in the treatment of multiple myeloma and advanced ovarian adenocarcinoma.
• Melphalan either alone or in combination with other drugs has a significant therapeutic effect in a proportion of patients suffering from advanced breast carcinoma.
• Melphalan is effective in the treatment of a proportion of patients suffering from polycythaemia vera.

Product Details:

• First-line treatment of chronic lymphocytic leukaemia (Binet stage B or C) in patients for whom fludarabine combination chemotherapy is not appropriate.
• Indolent non-Hodgkin''s lymphomas as monotherapy in patients who have progressed during or within 6 months following treatment with rituximab or a rituximab containing regimen.
• Front line treatment of multiple myeloma (Durie-Salmon stage II with progress or stage III) in combination with prednisone for patients older than 65 years who are not eligible for autologous stem cell transplantation and who have clinical neuropathy at time of diagnosis precluding the use of thalidomide or bortezomib containing treatment.

Product Details:

• Filgrastim injection is used to treat neutropenia (low white blood cells) that is caused by cancer medicines. It is a synthetic (man-made) form of a substance that is naturally produced in your body called a colony stimulating factor. Filgrastim helps the bone marrow to make new white blood cells.
• When certain cancer medicines are used to fight cancer cells, they also affect the white blood cells that fight infections. Filgrastim is used to prevent or reduce the risk of infection while you are being treated with cancer medicines. This medicine is also used to help the bone marrow recover after a bone marrow transplantation, for a process called peripheral blood progenitor cell collection in cancer patients, and to improve survival in cancer patients who have been exposed to radiation.

Product Details: